Also Clin0 autoimmune diseases; IGM-8444 3 trials Clin1 multiple cancers; IGM-7354 Clin1 solid & hematologic malignancies; IGM-2537 Clin0 multiple cancers; undisclosed RD undisclosed
IGM Biosciences is pioneering the development of IgM antibodies to treat disease. Current antibody therapies commonly use the Y-shaped IgG structure to bind specific targets; however, the IgM antibody structure may have greater binding power. IgG antibodies possess two binding units, while IgM antibodies have ten. IGM is using this structural baseline to create “super-antibodies” by improving the qualities of IgM antibodies and allowing production at scale. Increased binding avidity and affinity enables IGM to design IgM antibodies to target difficult antigens and also bind multiple targets simultaneously, opening up the translational capabilities of their products to different diseases from cancer to autoimmune. Clinical trials for Non-Hodgkin’s lymphoma are in progress.
PT Temporary Clinical Research Associate
Mountain View, CAHybrid|14 days ago
Temporary Clinical Trials Manager
Remote - USA/ Remote|17 days ago
Sr. Clinical Trials Manager
Remote - USA/ Remote|28 days ago